CY-101 is under clinical development by Cytovation and currently in Phase II for Liver Cancer. According to GlobalData, Phase II drugs for Liver Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CY-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CY-101 overview
CY-101 is under development for the treatment of cutaneous warts (papillomas) caused by human papilloma virus, metastatic melanoma, nasopharyngeal squamous cell carcinoma, head and neck squamous cell carcinoma (HNSCC) and triple-negative breast cancer (TNBC), recurrent respiratory papillomatosis (RRP), adrenocortical carcinoma, colorectal cancer, hepatocellular carcinoma and liver cancer. It is administered topically as cream for warts and intratumorally and subcutaneous for solid tumors and lymphoma. CyPep-1 is a tumor specific, cytotoxic peptide with extreme lipid penetrating properties. CyPep-1 targets the wart cells and induces rapid necrotic cell death. The drug candidate was also under development for the treatment of multi-resistant bacterial infections such as E.coli infections and skin cancer.
Cytovation overview
CytovationA (Cytovation) is a biotech company that develops novel therapeutic agents for skin diseases and infections. The company’s lead candidate includes CyPep-1 is a novel, first-in-class immunotherapy, that drives a tumor-specific immune response with a dual mode of action. CyPep-1 helps the immune system to fight cancer by exposing tumor neoantigens and inhibiting mechanisms that drive tumor growth and immune evasion. The company partners with pharmaceutical companies, scientific institutions and research organizations. Cytovation is headquartered in Bergen, Norway.
For a complete picture of CY-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
